Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.47 |
| ▸ | FDPS | P14324 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 7/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24599673 | 1.00 | SMPD1 (0.47) | SMPD1FDPSCES2FAAHCES1 | |
| SCHEMBL20857597 | 0.98 | FDPS (0.45) | SMPD1FDPSCES2FAAHCES1 | |
| SCHEMBL24599562 | 0.83 | SMPD1 (0.47) | SMPD1FDPSCES2FAAHCES1 | |
| SCHEMBL23987201 | 0.83 | SMPD1 (0.47) | SMPD1FDPSCES2FAAHCES1 | |
| SCHEMBL8895992 | 0.83 | CES2 (0.45) | FDPSCES2FAAHCES1MEN1 | |
| SCHEMBL13267820 | 0.83 | CES2 (0.45) | FDPSCES2FAAHCES1MEN1 | |
| SCHEMBL21117971 | 0.82 | FAAH (0.46) | SMPD1FDPSCES2FAAHCES1 | |
| SCHEMBL18386560 | 0.82 | SMPD1 (0.46) | SMPD1FDPSCES2FAAHCES1 | |
| SCHEMBL20169528 | 0.82 | CES2 (0.42) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL8899029 | 0.81 | FAAH (0.47) | CES2FAAHCES1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | SMPD1 417/4885FDPS 4746/4885CES2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.